Satellos Bioscience (NASDAQ:MSLE) Announces Earnings Results, Misses Estimates By $0.18 EPS

Satellos Bioscience (NASDAQ:MSLE) announced its earnings results on Thursday. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18), Zacks reports.

Satellos Bioscience Price Performance

MSLE opened at $9.82 on Friday. Satellos Bioscience has a 12 month low of $4.84 and a 12 month high of $13.39. The firm has a market cap of $204.65 million, a PE ratio of -6.14 and a beta of 1.51. The business’s fifty day moving average is $8.13.

Analysts Set New Price Targets

A number of analysts have issued reports on MSLE shares. Wall Street Zen upgraded shares of Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Satellos Bioscience in a research note on Friday, August 7th. Guggenheim assumed coverage on shares of Satellos Bioscience in a report on Tuesday, April 28th. They issued a “buy” rating and a $23.00 price objective for the company. Canaccord Genuity Group raised shares of Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. Finally, HC Wainwright increased their target price on shares of Satellos Bioscience from $11.00 to $18.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Satellos Bioscience currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.75.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.